CL2019000266A1 - Composición de cannabis. - Google Patents

Composición de cannabis.

Info

Publication number
CL2019000266A1
CL2019000266A1 CL2019000266A CL2019000266A CL2019000266A1 CL 2019000266 A1 CL2019000266 A1 CL 2019000266A1 CL 2019000266 A CL2019000266 A CL 2019000266A CL 2019000266 A CL2019000266 A CL 2019000266A CL 2019000266 A1 CL2019000266 A1 CL 2019000266A1
Authority
CL
Chile
Prior art keywords
cancer
understanding
pharmaceutical composition
cannabis composition
symptom associated
Prior art date
Application number
CL2019000266A
Other languages
English (en)
Spanish (es)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65524553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019000266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2017901222A external-priority patent/AU2017901222A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of CL2019000266A1 publication Critical patent/CL2019000266A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2019000266A 2016-08-03 2019-01-31 Composición de cannabis. CL2019000266A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370299P 2016-08-03 2016-08-03
AU2017901222A AU2017901222A0 (en) 2017-04-04 Cannabis composition
AU2017902065A AU2017902065A0 (en) 2017-05-31 Cannabis composition

Publications (1)

Publication Number Publication Date
CL2019000266A1 true CL2019000266A1 (es) 2019-10-04

Family

ID=65524553

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000266A CL2019000266A1 (es) 2016-08-03 2019-01-31 Composición de cannabis.

Country Status (15)

Country Link
US (2) US11304925B1 (https=)
EP (1) EP3493800A4 (https=)
JP (2) JP2019526541A (https=)
KR (3) KR102447510B1 (https=)
CN (1) CN109789123A (https=)
AU (4) AU2017305103B2 (https=)
BR (1) BR112019001794A2 (https=)
CA (1) CA3031300A1 (https=)
CL (1) CL2019000266A1 (https=)
CO (1) CO2019001043A2 (https=)
IL (1) IL264458B (https=)
MX (1) MX386086B (https=)
PE (2) PE20230607A1 (https=)
SG (1) SG11201900501RA (https=)
WO (1) WO2018023166A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
AU2018100837B4 (en) 2017-06-19 2019-02-21 Zelira Therapeutics Operations Pty Ltd Sleep Disorder Compositions and Treatments Thereof
CA3103178A1 (en) * 2017-06-27 2019-01-03 Enviro BioMedical Laboratories Inc. Blended cannabis compounds and methods of making the same
SG11202002169TA (en) * 2017-09-15 2020-04-29 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
CN112969452A (zh) * 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
US11946016B2 (en) 2018-06-14 2024-04-02 Biosoma B.V. Process for the extraction of oil-soluble components from plant material
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020084423A1 (en) * 2018-10-24 2020-04-30 Radient Technologies Innovations Inc. Extraction-based contract execution
CA3123773A1 (en) * 2018-12-12 2020-06-18 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
NL2022615B1 (en) * 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
FI3920891T3 (fi) * 2019-04-17 2024-03-19 Nordiccan As Nopeasti hajoavat kannabinoiditabletit
CA3154295A1 (en) * 2019-10-09 2021-04-15 Michael Foster DAVIS Aerosolisable material
CN118161552A (zh) * 2019-12-19 2024-06-11 史蒂文·罗斯斯坦 富含多酚化合物的提取物以及相关方法
CN115605289A (zh) * 2020-04-29 2023-01-13 利加尔有限合伙公司（Nz） 印迹聚合物及其使用方法
EP4146193A4 (en) * 2020-05-04 2024-05-29 Agronomed Management, LLC Topical anti-inflammatory cannabinoid compositions
WO2021248207A1 (en) * 2020-06-12 2021-12-16 Zelira Therapeutics Operations Pty Ltd Composition and method for treating chronic pain
WO2022191551A1 (ko) * 2021-03-08 2022-09-15 주식회사 엘지생활건강 칸나비게롤을 포함하는 조성물
IL307444A (en) * 2021-04-05 2023-12-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Preparations and methods for the treatment of cancer
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2025231524A1 (en) * 2024-05-08 2025-11-13 Heyday RX Pty Ltd Cannabinoid compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US8628796B2 (en) 2004-12-09 2014-01-14 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
WO2007032962A2 (en) 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
AU2013257322A1 (en) 2012-05-03 2014-11-20 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising delta9-tetrahydrocannabinol and a method for preparing such an isolate
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
US9095554B2 (en) 2013-03-15 2015-08-04 Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
LT3062606T (lt) 2013-10-29 2019-07-10 Biotech Institute, Llc Specializuotų kanapių selekcija, gamyba, perdirbimas ir panaudojimas
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
CA2996626A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
CN107205960A (zh) 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
MX385464B (es) 2014-12-12 2025-03-18 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
WO2016105514A1 (en) * 2014-12-23 2016-06-30 Biotech Institute, Llc A reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
IL253664B (en) 2015-01-31 2022-09-01 Constance Therapeutics Inc Production method for extracting oil from cannabis and preparations
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
CA3031811A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition

Also Published As

Publication number Publication date
US20220202767A1 (en) 2022-06-30
MX386086B (es) 2025-03-18
AU2018100920A4 (en) 2018-08-02
SG11201900501RA (en) 2019-02-27
AU2021205115B2 (en) 2023-06-15
WO2018023166A1 (en) 2018-02-08
BR112019001794A2 (pt) 2019-05-07
AU2017305103A1 (en) 2018-07-05
KR20220132674A (ko) 2022-09-30
JP2019526541A (ja) 2019-09-19
US11304925B1 (en) 2022-04-19
AU2021205115A1 (en) 2021-08-12
AU2019203529B2 (en) 2021-04-29
KR102447510B1 (ko) 2022-09-27
MX2019001286A (es) 2019-06-13
IL264458B (en) 2021-06-30
CN109789123A (zh) 2019-05-21
CA3031300A1 (en) 2018-02-08
KR20190034576A (ko) 2019-04-02
AU2017305103B2 (en) 2019-02-21
JP7139559B2 (ja) 2022-09-21
IL264458A (en) 2019-02-28
JP2021054836A (ja) 2021-04-08
KR20210129747A (ko) 2021-10-28
PE20230607A1 (es) 2023-04-13
EP3493800A4 (en) 2020-04-08
PE20200677A1 (es) 2020-06-11
EP3493800A1 (en) 2019-06-12
AU2019203529A1 (en) 2019-06-06
CO2019001043A2 (es) 2020-06-19
AU2018100920B4 (en) 2019-02-07
NZ750272A (en) 2021-09-24

Similar Documents

Publication Publication Date Title
CL2019000266A1 (es) Composición de cannabis.
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
CL2019000270A1 (es) Composición de cannabis.
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
CL2019000844A1 (es) Compuesto de piridina.
MX2019009695A (es) Inhibidores espirociclicos de catepsina c.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
BR112017018092A2 (pt) composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio.
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112017000714A2 (pt) indols funcionalizados e substituídos como agentes anti-câncer
MX391440B (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
BR112019003577A2 (pt) métodos de tratamento da semente e produtos resultantes
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
MX385372B (es) Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7